Changchun BCHT Biotechnology Co. (SHA:688276)
China · Delayed Price · Currency is CNY 20.10
+0.20 (1.01%)
At close: Feb 3, 2026
SHA:688276 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 677.51 | 1,229 | 1,825 | 1,071 | 1,201 | 1,440 |
Other Revenue | - | - | 0.14 | 0.05 | 0.75 | 1.36 |
| 677.51 | 1,229 | 1,825 | 1,071 | 1,202 | 1,441 | |
Revenue Growth (YoY) | -57.85% | -32.64% | 70.30% | -10.86% | -16.61% | 47.73% |
Cost of Revenue | 173.94 | 206.06 | 210.35 | 181.93 | 228.56 | 176.27 |
Gross Profit | 503.57 | 1,023 | 1,614 | 889.52 | 973.47 | 1,265 |
Selling, General & Admin | 488.92 | 582.83 | 800.93 | 552.73 | 555.93 | 689.48 |
Research & Development | 178.18 | 156.14 | 198.07 | 133.53 | 156.76 | 93.36 |
Other Operating Expenses | 7.49 | 9.83 | 13.04 | 9.7 | 10.58 | 10.67 |
Operating Expenses | 689.95 | 772.28 | 1,072 | 729.59 | 734.04 | 792.91 |
Operating Income | -186.38 | 250.74 | 541.96 | 159.93 | 239.43 | 472.18 |
Interest Expense | -2.69 | -1.52 | -0.7 | - | -0.33 | -4.05 |
Interest & Investment Income | 1.87 | 4.6 | 12.44 | 18.4 | 11.78 | 7.34 |
Earnings From Equity Investments | -24.84 | -0.44 | 0.69 | 0.31 | -1.02 | - |
Currency Exchange Gain (Loss) | 0.87 | 0.87 | 0.67 | 1.86 | -0.14 | -0.22 |
Other Non Operating Income (Expenses) | 25.7 | -0.25 | -0.21 | -0.15 | -0.16 | -0.16 |
EBT Excluding Unusual Items | -185.47 | 254 | 554.85 | 180.35 | 249.55 | 475.09 |
Gain (Loss) on Sale of Assets | -2.55 | -2.55 | -0.9 | -0.73 | -2.19 | - |
Asset Writedown | -45.24 | -0.78 | - | - | - | -0.05 |
Other Unusual Items | 4.41 | 4.41 | 2.91 | 18.07 | 14.2 | 11.61 |
Pretax Income | -228.16 | 255.77 | 563.76 | 197.69 | 261.57 | 486.65 |
Income Tax Expense | -57.63 | 23.68 | 62.75 | 16.16 | 18.01 | 68.42 |
Net Income | -170.53 | 232.09 | 501.01 | 181.54 | 243.55 | 418.23 |
Net Income to Common | -170.53 | 232.09 | 501.01 | 181.54 | 243.55 | 418.23 |
Net Income Growth | - | -53.67% | 175.98% | -25.46% | -41.77% | 89.23% |
Shares Outstanding (Basic) | 416 | 414 | 414 | 413 | 393 | 367 |
Shares Outstanding (Diluted) | 416 | 414 | 414 | 413 | 393 | 367 |
Shares Change (YoY) | 0.45% | 0.10% | 0.36% | 5.03% | 7.07% | 1.25% |
EPS (Basic) | -0.41 | 0.56 | 1.21 | 0.44 | 0.62 | 1.14 |
EPS (Diluted) | -0.41 | 0.56 | 1.21 | 0.44 | 0.62 | 1.14 |
EPS Growth | - | -53.72% | 175.00% | -29.03% | -45.61% | 86.89% |
Free Cash Flow | -224.07 | -135.92 | -215.46 | -250.91 | -492.58 | -126.58 |
Free Cash Flow Per Share | -0.54 | -0.33 | -0.52 | -0.61 | -1.25 | -0.34 |
Dividend Per Share | 0.169 | 0.169 | 0.150 | 0.150 | 0.100 | - |
Dividend Growth | 12.67% | 12.67% | - | 50.00% | - | - |
Gross Margin | 74.33% | 83.23% | 88.47% | 83.02% | 80.98% | 87.77% |
Operating Margin | -27.51% | 20.40% | 29.70% | 14.93% | 19.92% | 32.76% |
Profit Margin | -25.17% | 18.88% | 27.46% | 16.94% | 20.26% | 29.02% |
Free Cash Flow Margin | -33.07% | -11.06% | -11.81% | -23.42% | -40.98% | -8.78% |
EBITDA | -73.05 | 354.92 | 633.94 | 230.87 | 307.76 | 531.04 |
EBITDA Margin | -10.78% | 28.88% | 34.74% | 21.55% | 25.60% | 36.84% |
D&A For EBITDA | 113.33 | 104.18 | 91.99 | 70.94 | 68.34 | 58.86 |
EBIT | -186.38 | 250.74 | 541.96 | 159.93 | 239.43 | 472.18 |
EBIT Margin | -27.51% | 20.40% | 29.70% | 14.93% | 19.92% | 32.76% |
Effective Tax Rate | - | 9.26% | 11.13% | 8.17% | 6.89% | 14.06% |
Revenue as Reported | 677.51 | 1,229 | 1,825 | 1,071 | 1,202 | 1,441 |
Advertising Expenses | - | 435.57 | 568.76 | 371.28 | 411.83 | 540.22 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.